Citius Oncology (CTOR) Total Liabilities (2021 - 2026)

Citius Oncology (CTOR) has reported Total Liabilities for 6 consecutive years, with $71.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities rose 20.9% year-over-year to $71.7 million in Q2 2026; TTM through Jun 2026 was $71.7 million, a 20.9% increase from a year earlier, with the FY2025 full-year figure at $56.1 million, up 46.69% from the prior year.
• Total Liabilities was $71.7 million for Q2 2026 at Citius Oncology, up from $65.4 million in the prior quarter.
• Over five years, Total Liabilities peaked at $71.7 million in Q2 2026 and troughed at -$36.0 million in Q3 2022.
• A 5-year average of $46.9 million and a median of $53.7 million in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities soared 49590.45% in 2022 and plunged 57.98% in 2024, its largest moves.
• Over 5 years, Total Liabilities stood at $67.8 million in 2022, then decreased by 26.45% to $49.9 million in 2023, then retreated by 1.42% to $49.2 million in 2024, then increased by 4.81% to $51.6 million in 2025, then soared by 39.08% to $71.7 million in 2026.
• The last three Total Liabilities figures came in at $71.7 million (Q2 2026), $65.4 million (Q1 2026), and $51.6 million (Q4 2025), per Business Quant data.